secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009691
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics FY2023 net loss $46.5M; raised $177.2M in Q1 2024 financings
--------------------------------------------------------------------------------

- Net loss $46.5M ($0.17/share) vs $10.8M ($0.08) in FY2022; R&D expenses surged to $21.3M from $0.9M.
- Cash $9.2M at Dec 31, 2023; subsequent private placements & public offering raised ~$177.2M gross in Q1 2024.
- Phase 1/2a trials for [212Pb]VMT-α-NET (NETs) and [212Pb]VMT01 (melanoma) advanced; Cohort 2 enrolling.
- Entered collaboration with Bristol Myers Squibb for VMT01+nivolumab combo; Lantheus gets option for VMT-α-NET license.
- Acquired radiopharmaceutical manufacturing facility in Somerset, NJ; sold brachytherapy business to GT Medical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/0001437749-24-009691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/isr20240327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer